|
|
|
|
| LEADER |
01881nam a2200385 u 4500 |
| 001 |
EB001888686 |
| 003 |
EBX01000000000000001052047 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200106 r ||| eng |
| 100 |
1 |
|
|a Wells, Charlotte
|
| 245 |
0 |
0 |
|a High dose influenza vaccine for adults
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Charlotte Wells, Aleksandra Grobelna
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2019, January 8, 2019
|
| 300 |
|
|
|a 1 PDF file (45 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Influenza Vaccines / economics
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Aged
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Influenza, Human / drug therapy
|
| 653 |
|
|
|a Influenza Vaccines / therapeutic use
|
| 653 |
|
|
|a Guidelines as Topic
|
| 700 |
1 |
|
|a Grobelna, Aleksandra
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK541617
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The purpose of this review is to evaluate the comparative clinical evidence of high-dose influenza vaccination compared with standard-dose (and double-dose) influenza vaccine or placebo. Additionally, the comparative cost effectiveness and evidence-based guidelines were analyzed to facilitate and support decision making with regards to high-dose influenza vaccine
|